Advertisement

Advertisement

HALO Stock Latest News

Halozyme Buy Rating Reiterated as Analyst Sees Limited Medicare Pricing Risk and Maintains $93 Price Target

RatingsHalozyme Buy Rating Reiterated as Analyst Sees Limited Medicare Pricing Risk and Maintains $93 Price Target

Halozyme Earnings Call Highlights Royalty-Fueled Growth

PremiumCompany Announcements

Halozyme Earnings Call Highlights Royalty-Fueled Growth

1M ago

Halozyme price target lowered to $93 from $96 at Morgan Stanley

PremiumThe Fly

Halozyme price target lowered to $93 from $96 at Morgan Stanley

1M ago

Halozyme Maintained at Buy as Strong Execution and Shareholder Returns Offset Modest Price Target Trim to $93

PremiumRatings

Halozyme Maintained at Buy as Strong Execution and Shareholder Returns Offset Modest Price Target Trim to $93

1M ago

Analyst Reiterates Buy on Halozyme, Citing Underappreciated Growth and Maintaining $96 Price Target

PremiumRatings

Analyst Reiterates Buy on Halozyme, Citing Underappreciated Growth and Maintaining $96 Price Target

1M ago

Halozyme reports Q1 non-GAAP EPS $1.60, consensus $1.52

PremiumThe FlyHalozyme reports Q1 non-GAAP EPS $1.60, consensus $1.52

1M ago

Halozyme still sees 2026 non-GAAP EPS $7.75 to $8.25, consensus $8.09

The Fly

Halozyme still sees 2026 non-GAAP EPS $7.75 to $8.25, consensus $8.09

1M ago

HALO Earnings this Week: How Will it Perform?

Pre-Earnings

HALO Earnings this Week: How Will it Perform?

1M ago

Halozyme Stockholders Back Board, Pay and Auditor Choices

PremiumCompany Announcements

Halozyme Stockholders Back Board, Pay and Auditor Choices

1M ago

Halozyme announces global collaboration and license agreement with GSK

PremiumThe Fly

Halozyme announces global collaboration and license agreement with GSK

1M ago

Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis

PremiumThe Fly

Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis

2M ago

Halozyme names Darren Snellgrove as CFO

PremiumThe Fly

Halozyme names Darren Snellgrove as CFO

2M ago

Halozyme Appoints New Chief Financial Officer to Drive Growth

PremiumCompany AnnouncementsHalozyme Appoints New Chief Financial Officer to Drive Growth

2M ago

Halozyme price target raised to $95 from $90 at H.C. Wainwright

The Fly

Halozyme price target raised to $95 from $90 at H.C. Wainwright

2M ago

Halozyme price target raised to $96 from $94 at Morgan Stanley

The Fly

Halozyme price target raised to $96 from $94 at Morgan Stanley

2M ago

Halozyme: Underappreciated, Durable Royalty-Driven Growth Beyond 2028 Supports Buy Rating

PremiumRatings

Halozyme: Underappreciated, Durable Royalty-Driven Growth Beyond 2028 Supports Buy Rating

2M ago

Halozyme enters global global collaboration and license agreement with Vertex

PremiumThe Fly

Halozyme enters global global collaboration and license agreement with Vertex

3M ago

Halozyme Names David Ramsay Interim Chief Financial Officer

PremiumCompany Announcements

Halozyme Names David Ramsay Interim Chief Financial Officer

3M ago

Halozyme names David Ramsay as Interim CFO

PremiumThe Fly

Halozyme names David Ramsay as Interim CFO

3M ago

Halozyme price target raised to $94 from $78 at Morgan Stanley

PremiumThe FlyHalozyme price target raised to $94 from $78 at Morgan Stanley

4M ago

Halozyme price target raised to $90 from $75 at Benchmark

The Fly

Halozyme price target raised to $90 from $75 at Benchmark

4M ago

Halozyme price target raised to $75 from $65 at Wells Fargo

The Fly

Halozyme price target raised to $75 from $65 at Wells Fargo

4M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >